Cargando…
Harnessing Naturally Occurring Tumor Immunity: A Clinical Vaccine Trial in Prostate Cancer
BACKGROUND: Studies of patients with paraneoplastic neurologic disorders (PND) have revealed that apoptotic tumor serves as a potential potent trigger for the initiation of naturally occurring tumor immunity. The purpose of this study was to assess the feasibility, safety, and immunogenicity of an a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931687/ https://www.ncbi.nlm.nih.gov/pubmed/20824184 http://dx.doi.org/10.1371/journal.pone.0012367 |
_version_ | 1782186070026223616 |
---|---|
author | Frank, Mayu O. Kaufman, Julia Tian, Suyan Suárez-Fariñas, Mayte Parveen, Salina Blachère, Nathalie E. Morris, Michael J. Slovin, Susan Scher, Howard I. Albert, Matthew L. Darnell, Robert B. |
author_facet | Frank, Mayu O. Kaufman, Julia Tian, Suyan Suárez-Fariñas, Mayte Parveen, Salina Blachère, Nathalie E. Morris, Michael J. Slovin, Susan Scher, Howard I. Albert, Matthew L. Darnell, Robert B. |
author_sort | Frank, Mayu O. |
collection | PubMed |
description | BACKGROUND: Studies of patients with paraneoplastic neurologic disorders (PND) have revealed that apoptotic tumor serves as a potential potent trigger for the initiation of naturally occurring tumor immunity. The purpose of this study was to assess the feasibility, safety, and immunogenicity of an apoptotic tumor-autologous dendritic cell (DC) vaccine. METHODS AND FINDINGS: We have modeled PND tumor immunity in a clinical trial in which apoptotic allogeneic prostate tumor cells were used to generate an apoptotic tumor-autologous dendritic cell vaccine. Twenty-four prostate cancer patients were immunized in a Phase I, randomized, single-blind, placebo-controlled study to assess the safety and immunogenicity of this vaccine. Vaccinations were safe and well tolerated. Importantly, we also found that the vaccine was immunogenic, inducing delayed type hypersensitivity (DTH) responses and CD4+ and CD8+ T cell proliferation, with no effect on FoxP3+ regulatory T cells. A statistically significant increase in T cell proliferation responses to prostate tumor cells in vitro (p = 0.002), decrease in prostate specific antigen (PSA) slope (p = 0.016), and a two-fold increase in PSA doubling time (p = 0.003) were identified when we compared data before and after vaccination. CONCLUSIONS: An apoptotic cancer cell vaccine modeled on naturally occurring tumor immune responses in PND patients provides a safe and immunogenic tumor vaccine. (ClinicalTrials.gov number NCT00289341). TRIAL REGISTRATION: ClinicalTrials.gov NCT00289341 |
format | Text |
id | pubmed-2931687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-29316872010-09-03 Harnessing Naturally Occurring Tumor Immunity: A Clinical Vaccine Trial in Prostate Cancer Frank, Mayu O. Kaufman, Julia Tian, Suyan Suárez-Fariñas, Mayte Parveen, Salina Blachère, Nathalie E. Morris, Michael J. Slovin, Susan Scher, Howard I. Albert, Matthew L. Darnell, Robert B. PLoS One Research Article BACKGROUND: Studies of patients with paraneoplastic neurologic disorders (PND) have revealed that apoptotic tumor serves as a potential potent trigger for the initiation of naturally occurring tumor immunity. The purpose of this study was to assess the feasibility, safety, and immunogenicity of an apoptotic tumor-autologous dendritic cell (DC) vaccine. METHODS AND FINDINGS: We have modeled PND tumor immunity in a clinical trial in which apoptotic allogeneic prostate tumor cells were used to generate an apoptotic tumor-autologous dendritic cell vaccine. Twenty-four prostate cancer patients were immunized in a Phase I, randomized, single-blind, placebo-controlled study to assess the safety and immunogenicity of this vaccine. Vaccinations were safe and well tolerated. Importantly, we also found that the vaccine was immunogenic, inducing delayed type hypersensitivity (DTH) responses and CD4+ and CD8+ T cell proliferation, with no effect on FoxP3+ regulatory T cells. A statistically significant increase in T cell proliferation responses to prostate tumor cells in vitro (p = 0.002), decrease in prostate specific antigen (PSA) slope (p = 0.016), and a two-fold increase in PSA doubling time (p = 0.003) were identified when we compared data before and after vaccination. CONCLUSIONS: An apoptotic cancer cell vaccine modeled on naturally occurring tumor immune responses in PND patients provides a safe and immunogenic tumor vaccine. (ClinicalTrials.gov number NCT00289341). TRIAL REGISTRATION: ClinicalTrials.gov NCT00289341 Public Library of Science 2010-09-01 /pmc/articles/PMC2931687/ /pubmed/20824184 http://dx.doi.org/10.1371/journal.pone.0012367 Text en Frank et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Frank, Mayu O. Kaufman, Julia Tian, Suyan Suárez-Fariñas, Mayte Parveen, Salina Blachère, Nathalie E. Morris, Michael J. Slovin, Susan Scher, Howard I. Albert, Matthew L. Darnell, Robert B. Harnessing Naturally Occurring Tumor Immunity: A Clinical Vaccine Trial in Prostate Cancer |
title | Harnessing Naturally Occurring Tumor Immunity: A Clinical Vaccine Trial in Prostate Cancer |
title_full | Harnessing Naturally Occurring Tumor Immunity: A Clinical Vaccine Trial in Prostate Cancer |
title_fullStr | Harnessing Naturally Occurring Tumor Immunity: A Clinical Vaccine Trial in Prostate Cancer |
title_full_unstemmed | Harnessing Naturally Occurring Tumor Immunity: A Clinical Vaccine Trial in Prostate Cancer |
title_short | Harnessing Naturally Occurring Tumor Immunity: A Clinical Vaccine Trial in Prostate Cancer |
title_sort | harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931687/ https://www.ncbi.nlm.nih.gov/pubmed/20824184 http://dx.doi.org/10.1371/journal.pone.0012367 |
work_keys_str_mv | AT frankmayuo harnessingnaturallyoccurringtumorimmunityaclinicalvaccinetrialinprostatecancer AT kaufmanjulia harnessingnaturallyoccurringtumorimmunityaclinicalvaccinetrialinprostatecancer AT tiansuyan harnessingnaturallyoccurringtumorimmunityaclinicalvaccinetrialinprostatecancer AT suarezfarinasmayte harnessingnaturallyoccurringtumorimmunityaclinicalvaccinetrialinprostatecancer AT parveensalina harnessingnaturallyoccurringtumorimmunityaclinicalvaccinetrialinprostatecancer AT blacherenathaliee harnessingnaturallyoccurringtumorimmunityaclinicalvaccinetrialinprostatecancer AT morrismichaelj harnessingnaturallyoccurringtumorimmunityaclinicalvaccinetrialinprostatecancer AT slovinsusan harnessingnaturallyoccurringtumorimmunityaclinicalvaccinetrialinprostatecancer AT scherhowardi harnessingnaturallyoccurringtumorimmunityaclinicalvaccinetrialinprostatecancer AT albertmatthewl harnessingnaturallyoccurringtumorimmunityaclinicalvaccinetrialinprostatecancer AT darnellrobertb harnessingnaturallyoccurringtumorimmunityaclinicalvaccinetrialinprostatecancer |